FDA
- Status: approved
🇺🇸 Livopan in United States
6 US adverse-event reports
Marketing authorisation
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 6
Most-reported reactions
- Cholecystitis Infective — 1 report (16.67%)
- Cholelithiasis — 1 report (16.67%)
- Depressed Level Of Consciousness — 1 report (16.67%)
- Oxygen Saturation Decreased — 1 report (16.67%)
- Seizure — 1 report (16.67%)
- Umbilical Hernia — 1 report (16.67%)
Livopan in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Livopan approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Livopan in United States?
Federal University of Minas Gerais is the originator. The local marketing authorisation holder may differ — check the official source linked above.